Studies a clot-removal device for stroke caused by a blocked large artery
Follows adults with sudden stroke from a blocked large vessel treated with a clot retriever.
Plain-language title generated from the registry record
Registry title: EmboTrap ® II Revascularization Device (Neuravi) in Acute Ischemic Stroke
Key facts
- Where
- Milan, ItalySee the site
Where in Italy
- ASST GOM NiguardaMilan, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Niguarda Hospital
- Trial code
- NCT03601702
- Record updated
- 16 April 2026
- Original description
The primary aim of Registrap study is to assess the safety and effectiveness of the EmboTrap®II Clot Retriever device (Neuravi) in patients with acute ischemic stroke from large vessel occlusion.Read full original descriptionShow less
Multicentric Observational Prospective Study on the Use of the EmboTrap ® II Revascularization Device (Neuravi) in Acute Ischemic Stroke
The primary aim of Registrap study is to assess the safety and effectiveness of the EmboTrap®II Clot Retriever device (Neuravi) in patients with acute ischemic stroke from large vessel occlusion.
Inclusion: Signed Informed Consent Form; Large Vessel Occlusion on CTA or MRA in the Anterior or Posterior Proximal Cerebral Vasculature up to A1, M1, Dominant M2, P1; ASPECTS ≥ 6; Mismatch or good collaterals showed at MR or multiphasic CTA or pCT; Groin Puncture performed within 12 hours from symptom onset; Use of EmboTrap® II Revascularization Device (Neuravi) as the first or second line treatment.
Exclusion: Informed consent not given; Extracranial or tandem occlusion.